Sanofi Pasteur Starts a Phase II Vaccine Trial for Primary Prevention of Clostridium Difficile
Monday, November 29, 2021 9:01 AM

Related Stories



Vaccine Against one of the Most Common Causes of Hospital-acquired Infection in North America & Europe Tested in the U.S.

SWIFTWATER, Pennsylvania, November 29, 2021 /PRNewswire-FirstCall/ -- Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today that it has started its phase II clinical study of a vaccine for primary prevention of Clostridium difficile infection (CDI). The trial starting in the United States is focused on evaluating prevention of the first episode of CDI in at-risk individuals, which includes adults with imminent hospitalization or current or impending residence in a long-term care or rehabilitation facility.

The incidence of CDI has increased significantly in recent years in both North America and Europe. CDI-related treatments in these two regions of the world are estimated to be costing more than $7 billion a year. The recent emergence and spread of a hyper-virulent strain of C. difficile further highlights the importance of preventing CDI.

C. difficile is present worldwide and has become the most frequent hospital-acquired infection in the U.S., Europe, and Canada. Standard treatment of C. difficile infection involves the use of antibiotics. The Sanofi Pasteur trial is investigating the safety and immunogenicity of different formulations of a Clostridium difficile toxoid vaccine administered in adults aged 40 to 75 years who are at risk of C. difficile infection.

"Sanofi Pasteur has chosen a well established approach for this particular vaccine Toxoids have been used as the basis of a number of highly successful vaccines," explained Michel DeWilde, PhD, Senior Vice President for R&D at Sanofi Pasteur."This candidate vaccine has completed phase I clinical trials in more than 200 participants to evaluate its safety and immunogenicity."

The U.S. Food and Drug Administration (FDA) recently granted fast-track designation to Sanofi Pasteur's investigational Clostridium difficile vaccine candidate. The fast-track program of the FDA is designed to facilitate the development and expedite the review of new drugs and vaccines that are intended to treat or prevent serious or life-threatening conditions and demonstrate the potential to address unmet medical needs.

The phase II trial hopes to recruit approximately 650 participants at some 30 health-care centers across the U.S. For more information on the trial and the sites conducting the study, go to http://www.Clintrials.gov.

About C. difficile

C. difficile is an anaerobic spore-forming bacterium, present asymptomatically in approximately 60 percent of infants and approximately three percent of healthy adults. It belongs to the Clostridium family of bacteria, which also includes C. tetani (tetanus) and C. botulinum (botulism). The C. difficile bacteria produce two potent toxins: A and B. When the natural microbial flora of the gut is disturbed, usually as a result of antibiotic treatment for other illnesses, and a patient is exposed to C. difficile spores, the bacteria can multiply and release the two toxins, which cause a broad range of gastrointestinal symptoms in humans known collectively as CDI.

Hospital-acquired infections caused by C. difficile are a considerable problem in many industrialized countries, including the U.S., Canada, and Europe. It is estimated that there are about 500,000 cases of CDI in the US alone[1], with annual costs to the healthcare system of $3.2 billion[2]. In the EU, assuming a population of about 460 million people, the healthcare costs of CDI are estimated to be around $4.4 billion per year.[3] Additional information is available at the US Centers for Disease Control and Prevention and UK Health Protection Agency C. difficile information pages[1],[4].

About sanofi-aventis

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY). For more information, please visit: http://www.sanofi-aventis.com

Sanofi Pasteur, the vaccines division of sanofi-aventis Group, provided more than 1.6 billion doses of vaccine in 2009, making it possible to immunize more than 500 million people across the globe. A world leader in the vaccine industry, Sanofi Pasteur offers the broadest range of vaccines protecting against 20 infectious diseases. The company's heritage, to create vaccines that protect life, dates back more than a century. Sanofi Pasteur is the largest company entirely dedicated to vaccines. Every day, the company invests more than EUR 1 million in research and development. For more information, please visit: http://www.sanofipasteur.com or http://www.sanofipasteur.us

References:

1. CDC: http://www.cdc.gov/ncidod/dhqp/id_Cdiff.html

2. O'Brien et al, The Emerging Infectious Challenge of Clostridium difficile-Associated Disease in Massachusetts Hospitals: Clinical and Economic Consequences. Infection Control and Hospital Epidemiology, 2007; 28(11):1219-1227

3. European Centre for Disease Prevention and Control, Emergence of Clostridium difficile-associated disease in North America and Europe, Clinical Microbiology and Infectious Diseases, 2006; 12 (Suppl. 6): 2-18

    4. HPA:
http://www.hpa.nhs.uk/webw/HPAweb&Page&HPAwebAutoListName/Page/1179744911867

Forward Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans" and similar expressions. Although sanofi-aventis' management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such products candidates, the absence of guarantee that the products candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities as well as those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in sanofi-aventis' annual report on Form 20-F for the year ended December 31, 2009. Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statements.

http://www.sanofipasteur.us

SOURCE Sanofi Pasteur

(Source: PR Newswire )
(Source: Quotemedia)
 

Sponsors

Symbol :

Advertisement

Market news:

  • Heavy snow hits air travel, roads across Europe Dec 18, 2021 07:13 AM

    • LONDON - Authorities say air travel across Europe has been disrupted by heavy snow, while rail services and roads were also affected by the blast of wintry weather.
    • In Britain, London's Gatwick airport closed its runway due to snow, while British Airways suspended all flights from London's Heathrow airport.
    • In a statement, Heathrow said more snow was expected and that staff were "planning for the worst."
      • Top US officer says Iran still driving for a bomb Dec 18, 2021 06:58 AM

        • MANAMA, Bahrain - Iran is trying to build a nuclear bomb, posing a threat to its neighbors, and the United States is "very ready" to counter Iran should it make a move, the top U.S. military officer said Saturday.
        • "The United States takes very seriously our security commitments in the Gulf region," Mullen said following a meeting with Bahrain's king.
        • Bahrain, directly across the Gulf from Iran, is home to a large U.S. Navy base that would be on the front lines of any war with Iran.
          • Obama pushes for nuke treaty ratification Dec 18, 2021 06:35 AM

            • WASHINGTON - President Barack Obama is warning that failure to ratify a new arms control treaty with Russia will undercut American leadership on scores of challenges it faces worldwide.
            • Obama used his weekly radio and Internet address Saturday to plead with the Senate to approve the treaty, a dearly held foreign policy priority in the waning days of Congress' lame-duck session.
            • Obama said without action on the pact, known as New START, "we'll risk undermining American leadership not only on nuclear proliferation, but a host of other challenges around the world."
              • US lawmakers may vote on Armenian genocide measure Dec 18, 2021 06:06 AM

                • WASHINGTON - The House may vote next week on a measure that could damage U.S. relations with critical ally Turkey: a resolution declaring the World War I-era killings of Armenians a genocide.
                • House Democratic leaders had long set aside consideration of the draft resolution, and the measure was expected to expire as a new Republican-led House takes office next month.
                • House aides, speaking on condition of anonymity because they were not authorized to comment, said Friday that Democratic leaders have been discussing a possible vote with lawmakers.
                  • Senate nears repeal of military's curbs on gays Dec 18, 2021 06:06 AM

                    • WASHINGTON - Congress is close to ending the ban on gays serving openly in the military, with the Senate ready for a landmark vote that could deliver a major victory to the gay community, liberals and President Barack Obama.
                    • Senators planned a procedural vote Saturday on a bill ending the Pentagon's "don't ask, don't tell" policy as lawmakers held an unusual weekend session in their race to finish the year's legislative business.
                    • If at least 60 senators vote to advance the bill as expected, the repeal, which passed the House this week, could win final passage by late afternoon.

                      More news


Advertisement

    Recent Estimates

AnalystFirm NameSymbolEPS Estimate
jomariXXXXX CVG$0.31
XXXXXXXXXX RIMM$1.64
XXXXXXXXXX CRM$0.19
GEOXXXXX PAY$0.30
mrbilltraderXXXXX POT$1.59
XXXXXXXXXX OVTI$0.43
sam farahanXXXXX TECD$0.95
XXXXXXXXXX GSS$0.05
XXXXXXXXXX ABB$0.31
adfgafg ERTS$0.48